Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 15/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.34 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.34 |
| ▸ | SLC16A7 | O60669 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106516 | 0.85 | SLC16A1 (0.39) | SLC16A1CYP3A4CYP2C9SLC16A3SLC16A7 | |
| SCHEMBL5100173 | 0.85 | SLC16A1 (0.39) | SLC16A1CYP3A4CYP2C9SLC16A3SLC16A7 | |
| SCHEMBL5106258 | 0.84 | SLC16A1 (0.42) | SLC16A1CYP3A4CYP2C9SLC16A3SLC16A7 | |
| SCHEMBL5099956 | 0.82 | SLC16A1 (0.41) | SLC16A1CYP3A4CYP2C9SLC16A3SLC16A7 | |
| SCHEMBL5106262 | 0.76 | SLC16A1 (0.42) | SLC16A1CYP3A4CYP2C9SLC16A3SLC16A7 | |
| SCHEMBL5106237 | 0.76 | SLC16A1 (0.41) | SLC16A1CYP3A4CYP2C9SLC16A3SLC16A7 | |
| SCHEMBL5099962 | 0.76 | SLC16A1 (0.40) | SLC16A1CYP3A4CYP2C9SLC16A3SLC16A7 | |
| SCHEMBL3868024 | 0.76 | SLC16A1 (0.44) | SLC16A1CYP3A4CYP2C9SLC16A3SLC16A7 | |
| SCHEMBL5100047 | 0.75 | SLC16A1 (0.41) | SLC16A1CYP3A4CYP2C9SLC16A3 | |
| SCHEMBL3834031 | 0.75 | SLC16A1 (0.53) | SLC16A1CYP3A4CYP2C9SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214579-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-7384951-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| EP-1587812-B1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2006-08-09 | — | — | EP | disclosed |
| US-20060052400-A1 | Thienopyriminediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214579-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | TPMT, TYMP, TYMS | SLC16A1 3968/4885CYP3A4 494/4885CYP2C9 419/4885 |
| US-20060052400-A1 | Thienopyriminediones and their use in the modulation of autoimmune disease | C5, HRH4, CYP2S1 | SLC16A1 4250/4885CYP3A4 77/4885CYP2C9 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.